A5065992876- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 and healthcare impacts
- Esophageal Cancer Research and Treatment
- Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- COVID-19 Clinical Research Studies
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Hypoxia, and Metabolism
- Renal cell carcinoma treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Liver physiology and pathology
- Chemotherapy-related skin toxicity
Hospital Universitario 12 De Octubre
2015-2025
Research Institute Hospital 12 de Octubre
2010-2025
Hospital Universitario Virgen de las Nieves
2024
Hospital Universitario HM Sanchinarro
2013-2014
Spanish National Cancer Research Centre
2011-2013
Hospital Royo Villanova
2013
Centro de Investigación del Cáncer
2012
Cancer Research Center
2012
Hospital Universitario de Fuenlabrada
2012
Cancer Clinic
2011
Previous studies have highlighted the importance of an appropriate human epidermal growth factor receptor 2 (HER2) evaluation for proper identification patients eligible treatment with anti-HER2 targeted therapies. Today, relationship remains unclear between level HER2 amplification and outcome HER2-positive gastric cancer treated first-line chemotherapy trastuzumab. The aim this study was to determine whether gene determined by HER2/CEP17 ratio copy number could significantly predict some...
There is currently no consensus on the most suitable treatment for recurrence of hepatocellular carcinoma (HCC) after liver transplantation. This open, multicenter, retrospective, uncontrolled cohort study was designed to evaluate safety and preliminary efficacy combined use a mammalian target rapamycin (mTOR) inhibitor sorafenib in this setting. In 31 patients who suffered from HCC transplantation, immunosuppressive therapy changed mTOR inhibitors, systemic with initiated. combination...
Previous studies have suggested a more frequent and severe course of novel coronavirus SARS-CoV-2 infection in cancer patients undergoing active oncologic treatment. Our aim was to describe the characteristics disease this population determine predictive factors for poor outcome terms respiratory distress (acute syndrome [ARDS]) or death.
To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in combination with a PD-1 inhibitor patients unresectable hepatocellular carcinoma (uHCC) liver-only disease ineligible for chemoembolization.NASIR-HCC is single-arm, multicenter, open-label, phase 2 trial that recruited from 2017 to 2019 who were naïve immunotherapy had tumors BCLC B2 substage (single or multiple beyond up-to-7 rule), unilobar segmental lobar portal vein invasion (PVI); no extrahepatic...
Aim To study the HER2 gene amplification or overexpression in patients with advanced gastric cancer (GC) and their association patient characteristics survival. Patients methods Tumour tissue samples from 148 GC were studied for by immunohistochemistry (IHC), fluorescence situ hybridisation (FISH) dual colour silver enhanced (dc-SISH) methods. Clinicopathological data all collected. Progression free survival overall also analysed. Results Mean age was 67 (33–83) years; 75% male subjects, 51%...
Abstract Background HER2-positive gastric cancer (GC) affects 7%–34% of patients with GC. Trastuzumab-based first-line treatment has become the standard care for advanced (AGC). However, there are no clinically validated biomarkers resistance to HER2-targeted therapies. Upregulation PI3K pathway and tyrosine kinase receptor (TKR) alterations have been noted as molecular mechanisms in breast cancer. Our study aimed perform a characterization AGC investigate role PI3K/Akt/mTOR signaling...
García-García E, Gómez-Martín C, Angulo B, Conde Suárez-Gauthier A, Adrados M, Perna Rodríguez-Peralto J L, Hidalgo M & López-Ríos F (2011) Histopathology59, 8–17 Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with novel fully automated dual-colour silver method Aims: Amplification the (HER2) gene has been reported carcinoma (GC). Accordingly, trastuzumab plus chemotherapy recently become new...
Patients with gastro-oesophageal adenocarcinoma tumour-positive lymph nodes (ypN+) or positive surgical margins (R1) following neoadjuvant chemotherapy and resection are at high risk of recurrence. Adjuvant nivolumab is effective in oesophageal/oesophagogastric junction cancer residual pathological disease chemoradiation surgery. Immune checkpoint inhibition has shown efficacy advanced cancer. We hypothesised that nivolumab/ipilimumab would be more than adjuvant high-risk (ypN+ and/or R1)...
Hepatocellular carcinoma (HCC) is the most common primary malignancy in liver and third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be offered to individuals at high risk for developing HCC. Accurate diagnosis, staging, function are crucial when determining optimal therapeutic approach. The BCLC staging system widely endorsed Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally multimodal...
4074 Background: The PI3K/Akt/mTOR pathway, a key regulator of cellular proliferation and angiogenesis, has emerged as contributor to hepatocarcinogenesis. Everolimus, an mTOR inhibitor, exhibits antineoplastic activity in preclinical experimental models HCC. Sorafenib, multi-tyrosine kinase (including Raf) is the only targeted therapy demonstrating survival benefit approved for first-line treatment patients with unresectable Enhanced efficacy may be achieved through dual inhibition...